175
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Sickle Cell Anemia and Hematological Neoplasias

Pages 1431-1434 | Published online: 01 Jul 2009

  • Zinzani. P.L.,. et al., (2(X)O) "Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients". Haematologica 85(9). 926-929.
  • Santoro, A., et al., (2000) "Gemciubine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study", J. Clin. Oncol. 18(13), 2615-2619
  • Abbruizese, J.L. (1996) "Phase I studies with the novel nucleoside analog gcnicitabine", Semin. Oncol 23(5 Suppl. 10), 25-31.
  • Plurkelt, W., et al., (1995) "Gemcitabine: metabolism, mechanisms of action, and self-potentiaiion". Semin. Oncol. 22(4 Suppl. 11). 3-10.
  • A.P Association. Solimando, D.A., et al. (1999) Drug Information Handbook for Oncology (Lexi-Comp, Hudson. Cleveland. OH).
  • Vickers, M.F., et al., (2000) "Nucleoside transporter proteins: emerging targets for drug discovery". Emerg. Ther. Targets 4(4). 515-539.
  • Cass, C.E., et al., (1999) "Nucleoside transporters of mammalian cells", Phann. Biotechnol. 12, 313-352.
  • Baldwin. S.A., et al., (1999) "Nucleoside transporters: molecular biology and implications for therapeutic development". Mol. Med. Today 5(5), 216 224.
  • Mackey. J.R., et al., (1998) "The role of nucleoside transport in anticancer drug resistance". Drug Resist. Updates 1(5). 310-324.
  • Mackey. J.R., et al., (1998) "Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines". Cancer Res. 58, 4349-4357.
  • Janowska-Wieczorek, A., et al. (1999) "Gemcitabine membrane transport capabilities of normal human hematopoietic progenitor (CD34 +) cells". Blood 94(10), 279a.
  • Mackey, J.R., et al., (2002) "Immunohistochemical variation of human equilibrative nucleoside transporter 1 (hENT1) protein in primary breast cancers". Clin. Cancer Res., 8, 110-116.
  • Cass, CE. Muzik, H. and Paterson. A.R. (1975) "Combination therapy of mouse leukemia L1210 by 1-beia-D-arabinofuranosylcytosine and 6-1(4-nitrobenzyl)thio)-9-beta-D-ribofuranosylpurine", Cancer Res. 35(5), 1187-1193.
  • Cass, C.E., et al., (1981) "Absence of binding sites for the transport inhibitor nitrobenzylthioinosme on nucleoside transport-deficient mouse lymphoma cells". Biachim. Biaphys. Acta 649(3). 769-777.
  • Cass., C.E., et al. (1992) "A comparison of the abilities of nitrobenzylthioinosine. dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin)", Cancer Res. 52(21), 5879-5886.
  • Paterson. A.R., et al., (1979) "Low specificity of the nucleoside transport mechanism of RPMl 6410 cells", MoI. Pharmucol. 16(3). 900-908.
  • Wiley. J.S., Jones. S.P. and Sawyer. W.H. (1983) "Cylosine arabinoside transport by human leukaemic cells". Eur. J Cancer Clin. Oncol. 19(8). 1067-1074.
  • Wiley. J.S., et al., (1982) "Cytosine arabinoside influx and nucleoside transport sites in acute leukemia". J. Clin. invert. 69(2). 479-489.
  • Gati, W.P., et al. (1998) "Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (arac)". Leuk. Lymph. 32, 45-54.
  • Gati, W.P., et al, (1997) "Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular cs nucleoside transporter site content measured by flow cytometry with SAENTA-fluorcscein". Blood 90(1), 346-353.
  • Wiley. J.S., et al., (1985) "Cytosine arahinosidc transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma". J. Clin. Invest. 75(2). 632-642.
  • Jennings, L.L., et al., (2001) "Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT) and hENT2) in the central nervous system", Neuropharmacology 40.722 731.
  • Lister, TA., et al. (1989) "Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting", J. Clin. Oncol. 7(11), 1630-1636.
  • Murray, P.C., et al. (1999) "Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease". Bhod 94(2). 442-447.
  • Jarred, A.F., Armstrong, A.A. and Alexander. O. (1996) "Epideminlogy of ERV and Hodgkin's lymphoma". Ann. Oncol. 7(Suppl. 4). 5-10.
  • Sanloro, A., et al. (1997) "Phase II study with gemcitabine in pretreated patients with Hodgkin's (HD) and non-Hodgkin's lymphomas (NHL): results of a multicenter study". Proc. Annu Meet. Am. Soc. Clin. Oncol. 16. A71.
  • Hanel, M., et al., (2001) "Salvage chemotherapy with mitoxantrone, fludarabine. cytarabine. and cisplatin (MIFAP) in relapsing and refractory lymphoma". J. Cancer Res. Clin. Oncol. 127(6). 387-395.
  • Betticher, D.C., et al. (1994) "High incidence of infections after 2chlorodcoxyadenosine (2-CDA) therapy in patients with malignant lympbotnas and chronic and acute leukaemias". Ann. Oncol. 5(1), 57-64.
  • Cummings. F.J., et al., (1991) "Phase Il trial of pentostalin in refractory lymphoraas and cutaneous T-cell disease". J Clin. Oncol. 9(4), 565-571
  • Martin, A., et al. (2001) "long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease". Br. J. Haematol. 113(1). 161-171.
  • Diehl, V. Mauch. P.M and Harris. N. L. (2000) "Hodgkin's disease. Chapter 45.6". In: DeVita, V.T., Hellmann, S. and Rosenberg, S.A., eds. Cancer: Principles and Practice of Oncnlogv (Lippincott Williams and Wilkins, Philadelphia, PA), pp 2339 2387.
  • Thomas. J., et al., (1992) "Phase II study of cytarabine in Hodgkin's disease. The EORTC Lymphoma Cooperative Group". Eur. J. Cancer. 857-859.
  • Wiley. J.S., Smith. CL. and Jamirson, G.P. (1991) "Transport of 2'-deoxycofonnycin in human leukemic and lymphoma cells". Biochem. Pharmacol 42(3). 708 710.
  • Kaplinsky, C., et ai. (1986) "Selective protection of tubercidin loxicity by nitrobenzyl thioinosine in normal tissues but notl in human neuroblastoma cells". Cancer Chemother. Pharmacol. 17(31.264-268.
  • Boumah, C.E., Hogue, D.L. and Cass, C.E. (1992) "Expression of high levels of nitrobenzylthioinosme-serjsiiive oucleoside transport in cultured human choriocarcinoma (BcWo) cells". Biochem. J. 2881 Pt 3). 987-996.
  • Pressacco, J., et al., (1995) "Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis". Br. J. Cancer 72(4), 939-942.
  • Cass, C.K., et all., (1979) "Fluctuations in nucleoside uptake and binding of the inhibitor of nucleoside transport, nitrobenzylthioi-nosine. during the replication cycle of HeLa cells". Cancer Res. 39(4). 1245-1252.
  • Wiley, J.S., et al., (1994) "Assessment of proliferative responses to granulocyte-macrophage colony-stimulating factor (GM-CSF) in acute myeloid leukaemia using a fluorescent ligaud for the nucleoside transporter". Leukemia 8(1). 181-185.
  • Smith, CL., et al., (1989) "Nucleoside transport and proliferative rate in human thymocytes and lymphocytes". Blood 74(6), 2038-2042.
  • Goh, L.B., Mack, P. and Lee. C.W. (1995) "Nitrobenzylthioinosinebinding protein overexpression in human breast, liver, stomach and colorectal tumour tissues". Anticancer Res. 15(6B). 2575-2579.
  • Fung, M.C., et al, (1999) "A review of hemolytic uremic syndrome in patients treated with gemcitabinc therapy". Cancer 85(9), 2023-2032.
  • Dumomet. C., et al., (2001) "Gemcitahbne as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma". Br. J. Haematol. 113(3). 772-778.
  • Pavlakis, N., et al., (1997) "Fatal pulmonary toxicity resulting from treatment with gemctabine", Cancer 80(2). 286-291.
  • [44| Gietema, J.A., et al (1998) "Effects of gemcitahine on renal function in patients with non-small cell lung cancer". Eur: J. Cancer 34(1). 199-202.
  • Fracasso, P.M., et al. (1999) "Membranoproliterativc glonierulonephritis following gerncitabine and vinorelbine chemotherapy for peritoneal mesothelioma", J. Nail Cancer Inst. 91(20). 1779-1780.
  • Bruns. CJ., et at., (2000) "Epidermal growth factor receptor blockade with C225 plus gerncitabine results in regression of human pancreatic carcinoma growing ortholopically in nude mice by anliangiogenic mechanisms", Clin. Cancer Res. 6(5). 1936-1948.
  • Trumper. L.H., et al., (1993) "Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations". Blood 81(11). 3097-3115.
  • Kuppers, R., et al., (1994) "Hodgkin disease: Hodgkin and Reed-Sternbcrg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development". Proc. Natl Acael. Sci. USA 91(23). 10962-10966
  • Kanzler, H., et al., (1996) "Hodgkin and Reed Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells", J. Exp. Med. 184(4). 1495-1505.
  • Jox, A., et al. (1998) "Detection of identical Hodgkin-RecdStemberg cell specific immunoglobulin gene rearrangements in a patient with Hodgkin's disease of mixed cellularily subtype at primary diagnosis and in relapse two and a half years later". Ann. Oncol 9(3), 283-287.
  • Hasenclever, D, and Diehl, V. (1998) "A prognostic score for advanced Hodgkin's disease International prognostic factors project on advanced Hodgkin's disease". N. Eng!. J. Med. 339(21). 1506-1514.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.